Milrinone Lactate In 5% Dextrose Injection, Solution
NDC 65145-177
Product Information
Milrinone Lactate In 5% Dextrose is a ANDA-approved product labeled by Caplin Steriles Limited. This medication is used for the short-term treatment of heart failure. It is supplied as a injection, solution for intravenous administration. This product entry covers the primary NDC 65145-177 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 65145-177?
What are the uses of this product?
What are Active Ingredients of this product?
- MILRINONE LACTATE .2 mg/mL - A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase type 3 activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the inotropic potency of amrinone.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- MILRINONE LACTATE (UNII: 9K8XR81MO8)
- MILRINONE (UNII: JU9YAX04C7) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- LACTIC ACID (UNII: 33X04XA5AT)
- DEXTROSE MONOHYDRATE (UNII: LX22YL083G)
- WATER (UNII: 059QF0KO0R)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Milrinone Injection
Milrinone injection is used to treat heart failure. Milrinone is in a class of medications called cardiotonic agents. It works by helping the heart to pump better.
[Learn More]
* Please review the full disclaimer at the bottom of this page.